Skip to content
FY'25FY'24FY'23FY'22
Profitability
Gross margin336%-11.5pp347.5%+6.2pp341.3%-5.3pp346.6%+2.6pp
Operating margin9.5%+30.8pp-21.2%+150pp-171.7%+143pp-314.9%+114pp
Net margin-11.1%+36.8pp-47.9%+185pp-232.7%+212pp-444.4%+50.9pp
Efficiency
Asset turnover2.7×+0.4×2.3×+0.6×1.7×+0.6×1.1×+0.2×
Liquidity
Current ratio11.1×-0.6×11.7×-1.5×13.2×-1.8×15×-3.3×
Leverage
Debt-to-equity3.2×
Per Share
Book value per share$12.77+1,396%-$0.99+88.3%-$8.39-386%$2.93-88.9%
Valuation
Market capitalization$189.63B+64.6%$115.22B+21.7%$94.68B+4.6%$90.51B+13.1%
Price / sales64.9×+12.0×52.9×-14.0×66.8×-28.6×95.4×-17.8×
Price / book573.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Alnylam Pharmaceuticals's profit margins?
Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
Where do Alnylam Pharmaceuticals's ratios come from?
Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.